198 related articles for article (PubMed ID: 33805660)
1. Novel PEGylated Lipid Nanoparticles Have a High Encapsulation Efficiency and Effectively Deliver MRTF-B siRNA in Conjunctival Fibroblasts.
Sanghani A; Kafetzis KN; Sato Y; Elboraie S; Fajardo-Sanchez J; Harashima H; Tagalakis AD; Yu-Wai-Man C
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33805660
[TBL] [Abstract][Full Text] [Related]
2. Non-Viral Gene Therapy in Trabecular Meshwork Cells to Prevent Fibrosis in Minimally Invasive Glaucoma Surgery.
Luo J; Tan G; Thong KX; Kafetzis KN; Vallabh N; Sheridan CM; Sato Y; Harashima H; Tagalakis AD; Yu-Wai-Man C
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432663
[TBL] [Abstract][Full Text] [Related]
3. Receptor-targeted liposome-peptide-siRNA nanoparticles represent an efficient delivery system for MRTF silencing in conjunctival fibrosis.
Yu-Wai-Man C; Tagalakis AD; Manunta MD; Hart SL; Khaw PT
Sci Rep; 2016 Feb; 6():21881. PubMed ID: 26905457
[TBL] [Abstract][Full Text] [Related]
4. Development of Targeted siRNA Nanocomplexes to Prevent Fibrosis in Experimental Glaucoma Filtration Surgery.
Fernando O; Tagalakis AD; Awwad S; Brocchini S; Khaw PT; Hart SL; Yu-Wai-Man C
Mol Ther; 2018 Dec; 26(12):2812-2822. PubMed ID: 30301666
[TBL] [Abstract][Full Text] [Related]
5. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
[TBL] [Abstract][Full Text] [Related]
6. Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis.
Yu-Wai-Man C; Spencer-Dene B; Lee RMH; Hutchings K; Lisabeth EM; Treisman R; Bailly M; Larsen SD; Neubig RR; Khaw PT
Sci Rep; 2017 Mar; 7(1):518. PubMed ID: 28364121
[TBL] [Abstract][Full Text] [Related]
7. Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy.
Shobaki N; Sato Y; Suzuki Y; Okabe N; Harashima H
J Control Release; 2020 Sep; 325():235-248. PubMed ID: 32649972
[TBL] [Abstract][Full Text] [Related]
8. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
Hashiba K; Sato Y; Harashima H
J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
[TBL] [Abstract][Full Text] [Related]
9. Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity.
Konca YU; Kirshenbaum K; Zuckermann RN
Int J Nanomedicine; 2014; 9():2271-85. PubMed ID: 24872690
[TBL] [Abstract][Full Text] [Related]
10. Efficient Delivery of Globotriaosylceramide Synthase siRNA using Polyhistidine-Incorporated Lipid Nanoparticles.
Kim IG; Jung WH; You G; Lee H; Shin YJ; Lim SW; Chung BH; Mok H
Macromol Biosci; 2023 Apr; 23(4):e2200423. PubMed ID: 36728673
[TBL] [Abstract][Full Text] [Related]
11. Myocardin-related transcription factor contributes to renal fibrosis through the regulation of extracellular microenvironment surrounding fibroblasts.
Yamamura Y; Sakai N; Iwata Y; Lagares D; Hara A; Kitajima S; Toyama T; Miyagawa T; Ogura H; Sato K; Oshima M; Nakagawa S; Tamai A; Horikoshi K; Matsuno T; Yamamoto N; Hayashi D; Toyota Y; Kaikoi D; Shimizu M; Tager AM; Wada T
FASEB J; 2023 Jul; 37(7):e23005. PubMed ID: 37289107
[TBL] [Abstract][Full Text] [Related]
12. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
13. Spray drying siRNA-lipid nanoparticles for dry powder pulmonary delivery.
Zimmermann CM; Baldassi D; Chan K; Adams NBP; Neumann A; Porras-Gonzalez DL; Wei X; Kneidinger N; Stoleriu MG; Burgstaller G; Witzigmann D; Luciani P; Merkel OM
J Control Release; 2022 Nov; 351():137-150. PubMed ID: 36126785
[TBL] [Abstract][Full Text] [Related]
14. Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery.
Patel P; Fetse J; Lin CY; Guo Y; Hasan MR; Nakhjiri M; Zhao Z; Jain A; Cheng K
Acta Biomater; 2022 Dec; 154():374-384. PubMed ID: 36191773
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Lipid Nanoparticles Containing Ionizable Cationic Lipids Using Design-of-Experiments Approach.
Terada T; Kulkarni JA; Huynh A; Chen S; van der Meel R; Tam YYC; Cullis PR
Langmuir; 2021 Jan; 37(3):1120-1128. PubMed ID: 33439022
[TBL] [Abstract][Full Text] [Related]
17. Molecular-Level Structural Analysis of siRNA-Loaded Lipid Nanoparticles by
Ueda K; Sakagawa Y; Saito T; Fujimoto T; Nakamura M; Sakuma F; Kaneko S; Tokumoto T; Nishimura K; Takeda J; Arai Y; Yamamoto K; Ikeda Y; Higashi K; Moribe K
Mol Pharm; 2023 Sep; 20(9):4729-4742. PubMed ID: 37606988
[No Abstract] [Full Text] [Related]
18. Light-Activated siRNA Endosomal Release (LASER) by Porphyrin Lipid Nanoparticles.
Mo Y; Cheng MHY; D'Elia A; Doran K; Ding L; Chen J; Cullis PR; Zheng G
ACS Nano; 2023 Mar; 17(5):4688-4703. PubMed ID: 36853331
[TBL] [Abstract][Full Text] [Related]
19. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
[TBL] [Abstract][Full Text] [Related]
20. Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance.
Zhang J; Pei Y; Zhang H; Wang L; Arrington L; Zhang Y; Glass A; Leone AM
Mol Pharm; 2013 Jan; 10(1):397-405. PubMed ID: 23210488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
